尤瑞克林与依达拉奉治疗急性颈内动脉系统缺血性卒中的临床对比研究

目的 以依达拉奉作对比，探讨尤瑞克林治疗急性缺血性卒中的疗效及安全性。方法 将178例急性缺血性卒中患者随机分为治疗组和对照组，治疗组88例用尤瑞克林0.15PNA单位加入生理盐水250ml静脉滴注，每日1次，共14d为一疗程。对照组90例用依达拉奉30mg加入生理盐水250ml静脉滴注，每日2次共14d为一疗程。治疗前、治疗后14d进行美国国立卫生研究院卒中量表（the National Institutes of Health Stroke Scale，NIHSS）评分,并监测C反应蛋白（C-reactive protein，C-RP）、神经元烯醇化酶（neuron-specificenolase，NSE）变化,治疗前、治疗后14d、治疗后90d行Barthel指数评分。结果 治疗组和对照组治疗前、后的NIHSS评分比较均有统计学差异（P＜0.01）；而两组间的比较无统计学差异（P=0.5867）。治疗组和对照组治疗后第14d的Barthel评分比较无明显差异，治疗后90d的Barthel指数评分出现差异，治疗组优于对照组（P=0.004）。治疗组和对照组治疗后的血清C-RP及NSE值较治疗前下降，差异具有统计学意义，而两组间的比较差异无统计学意义。结论 尤瑞克林治疗急性缺血性卒中，有效、安全，急性期疗效不亚于依达拉奉，而远期疗效优于依达拉奉。

Clinicl Comparative Study on Urinary Kallidinogenase Treatment for Acute Cerebral Infarction

Objective To explore the curative effect and security of Urinary Kallidinogenase for acute cerebral infarction comparing to cerebral protective agent Edaravone injection. Methods One hundred and seventy-eight cases of patients with acute cerebral infarction were randomly divided into Urinary Kallidinogenase treatment group and Edaravone control group. The treatment group： 88 cases were treated with Urinary Kallidinogenase 0.15PNA solved in normal saline 250ml intravenous drip once a day for two weeks. The control group： 90 cases were treated with Edaravone 30mg solved in normal saline 250ml intravenous drip twice a day for two weeks （a total of 14 days for one course of treatment）. To compare the National Institutes of Health Stroke Scale （NIHSS） score, Barthel index score and monitor these biochemical indexes of CRP, NSE pre-treatment, 14 days post-treatment, and 90 days post-treatment. Results The NIHSS score of treatment group and control group both showed significant difference between pre-treatment and post-treatment （P〈0.01）; But the comparison of the NIHSS score between the two groups showed no significant difference （P=0.5867）. Barthel Index score comparison： the Barthel Index score between the two groups showed no significant difference 14 days after treatment （P=0.2839）; but the two groups showed significant difference 90 days after treatment （P=0.004）. The NSE and C-RP values of treatment group and control group both showed significant difference between pre-treatment and post-treatment, but NSE and C-RP values of the treatment group showed no significant difference compared with the control group. Conclusion The effect of the treatment of Urinary Kallidinogenase for acute cerebral infarction is not less than edaravone, and Urinary Kallidinogenase has better long-term effect than edaravone.